TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05292976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Serial Methacholine dilutions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Serial Methacholine dilutions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine Chloride
Description: Serial Methacholine dilutions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine Chloride
Description: Serial Methacholine dilutions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methacholine Chloride
Description: Serial Methacholine dilutions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate HFA 0.09 mg (Reference)
Description: One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate HFA 0.18 mg (Reference)
Description: One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
Study: NCT04865055

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cyclic merocyanine
Description: long-UVA absorber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05292976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate HFA 0.09 mg (Test)
Description: One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate HFA 0.18 mg (Test)
Description: One actuation each from two different Test inhalation aerosols and one actuation each from two different placebo Reference inhalation aerosols.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
Study: NCT05571215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Five sessions of tDCS will be performed following completions of baseline data collection. This will include 3 sessions during week one and 2 sessions in week 2. A tDCS unit (neuroConn Ilmenau, Germany) will be applied to the left DLPFC with participants in the sitting position for a 20 minutes of tDCS. An anodal 2.0 mA current will be applied to each participant, including a 30-second ramp up at the beginning of stimulation and a 30 second ramp down period and the end of stimulation. The left DLPFC (F3 from EEG 10/20 system) will be located using the Beam F3 measurement system. These parameters are consistent with those used in current literature on tDCS for pain. tDCS procedures will be performed by the PI (CA).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Immediately following completion of each tDCS intervention, participants will be given a one-on-one PNE session provided also by the PT (CA), who is a licensed healthcare provider with expertise in delivery of the content. This educational session will last about 30 minutes. Initial sessions will involve discussion and questioning of participants about their own understanding of their pain and this information will be used to subsequently individualize the forthcoming educational sessions. The educational sessions will follow the content of Explain Pain, a patient booklet, and will include information on the neurophysiology of pain, pain as typical process, the transition from acute to chronic pain, neuroplasticity, central sensitization, factors that promote pain chronicity. Information will be presented verbally along with visuals on paper.
Study: NCT04160910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Hydroxytryptophan
Description: Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
Study: NCT05186259

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive functioning
Description: Evaluation of cognitive functioning by means of:~* Auditory Stroop test~* Detecting letters task~* Letter-number sequencing task

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive functioning
Description: Evaluation of cognitive functioning by means of:~* Auditory Stroop test~* Detecting letters task~* Letter-number sequencing task

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Listening effort
Description: Evaluation of listening effort by means of the modified version of the behavioral listening effort test based on a dual-task paradigm by Degeest, Keppler \& Corthals (2018) .

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Listening effort
Description: Evaluation of listening effort by means of the modified version of the behavioral listening effort test based on a dual-task paradigm by Degeest, Keppler \& Corthals (2018) .

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported psychological factors
Description: Evaluation of psychological factors by means of:~* Depression, Anxiety and Stress Scale (DASS-21)~* Beck Depression Inventory (BDI)~* Big Five Inventory (BFI)~* Connor-Davidson Resilience Scale

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported psychological factors
Description: Evaluation of psychological factors by means of:~* Depression, Anxiety and Stress Scale (DASS-21)~* Beck Depression Inventory (BDI)~* Big Five Inventory (BFI)~* Connor-Davidson Resilience Scale

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported psychological factors
Description: Evaluation of psychological factors by means of:~* Depression, Anxiety and Stress Scale (DASS-21)~* Beck Depression Inventory (BDI)~* Big Five Inventory (BFI)~* Connor-Davidson Resilience Scale

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported psychological factors
Description: Evaluation of psychological factors by means of:~* Depression, Anxiety and Stress Scale (DASS-21)~* Beck Depression Inventory (BDI)~* Big Five Inventory (BFI)~* Connor-Davidson Resilience Scale
Study: NCT06409559

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pelvic reconstruction
Description: interfragmentary screws placed through the plate or buttress plate applied under compression without interfragmentary lag or position screws

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pelvic reconstruction
Description: interfragmentary screws placed through the plate or buttress plate applied under compression without interfragmentary lag or position screws
Study: NCT05811884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements.
Study: NCT04703868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 10mg
Description: Part A: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 20mg
Description: Part B: 1 tablet administered before the breakfast during 7 days
Study: NCT04737421

Intervention type: DEVICE
Intervention: NobelActive TiUltra implant
Description: Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.

Intervention type: DEVICE
Intervention: NobelParallel CC TiUltra implants
Description: Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.

Intervention type: DEVICE
Intervention: NobelReplace CC TiUltra implants
Description: Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.

Intervention type: DEVICE
Intervention: Nobel Biocare N1 TiUltra TCC implants
Description: Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
Study: NCT06488638

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
Description: commercially available beetroot juice dietary nitrate supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
Description: commercially available beetroot juice dietary nitrate supplement
Study: NCT05871918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCbHP VS ddEC-THP
Description: The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCbHP VS ddEC-THP
Description: The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.
Study: NCT04964245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: accelometer
Description: the respiration parameters are measured using an accelometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermographic camera
Description: the respiration parameters are measured using an thermographic camera.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: the respiration parameters are measured using an electrical impedance tomograhy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mattress Sensor
Description: the respiration parameters are measured using an Mattress pressure
Study: NCT05413863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocon's Human Insulin R U-500
Description: Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocon's Human Insulin R U-500
Description: Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocon's Human Insulin R U-500
Description: Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocon's Human Insulin R U-500
Description: Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocon's Human Insulin R U-500
Description: Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocon's Human Insulin R U-500
Description: Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humulin® R U-500 (US Reference Product)
Description: Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humulin® R U-500 (US Reference Product)
Description: Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humulin® R U-500 (US Reference Product)
Description: Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humulin® R U-500 (US Reference Product)
Description: Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humulin® R U-500 (US Reference Product)
Description: Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humulin® R U-500 (US Reference Product)
Description: Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)
Study: NCT05219578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-224
Description: RTX-224 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-224
Description: RTX-224 monotherapy
Study: NCT05466188

Intervention type: DIAGNOSTIC_TEST
Intervention: CPC
Description: CPC

Intervention type: DIAGNOSTIC_TEST
Intervention: CPC
Description: CPC
Study: NCT06276764

Intervention type: DIAGNOSTIC_TEST
Intervention: LINFU®
Description: Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard imaging tests
Description: EUS, CH-EUS, CEUS, MRI/MRCP, PET/CT, CT
Study: NCT05846438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Showering 48 hours after surgery
Description: The main intervention is allowing patients to shower 48 hours after surgery
Study: NCT06262425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex
Description: It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation over primary motor cortex
Description: It will be applyed a magnetic field over the primary motor cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive Transcranial Magnetic Stimulation
Description: It will be applied a sham stimulation with the same protocol that pretends to create the illusion of being stimulated
Study: NCT01304628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL-3994
Description: subcutaneous PL-3994, single dose, 4 escalating dose groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PL-3994
Description: subcutaneous PL-3994, single dose, 4 escalating dose groups
Study: NCT05923502

Intervention type: DRUG
Intervention: Duvelisib
Description: This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
Study: NCT06483685

Intervention type: DRUG
Intervention: Radiopharmaceuticals drugs
Description: radiopharmaceuticals drugs included in the Anatomical Therapeutic Chemical (ATC) classification system.
Study: NCT04921878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome injection
Description: Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle) for a maximum of 6 cycles.
Study: NCT06468267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).
Study: NCT04366518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine Transdermal System
Description: Rivastigmine doses will be administered transdermally using 9.5 mg/24 hr transdermal patches. Participants will be randomized to two treatments with oral rivastigmine vs. placebo separated by a 15-hour washout period (\>5 half-lives to eliminate any residual effects). This will require three separate visits: a baseline visit, a visit for the first transdermal treatment and a visit for the second transdermal treatment. All visits include fMRI scans. The first transdermal patch will be administered 8-14 hours before the scan. After the washout period, the second transdermal patch will be administered 8-14 hours before the scan. No study team member except for the unblinded team member will know which capsule the participant receives first. Because we are interested in rivastigmine as a probe for a pre-identified computational/physiological abnormality, we will median-split groups post-hoc for the purposes of analysis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine
Description: The authors have chosen to use scopolamine to determine the effects of cholinergic antagonism, as treatment with scopolamine demonstrates a dose-related increase in propensity toward conditioned hallucinations and in doses much higher than those proposed here, can cause spontaneous hallucinations. At the proposed dose, scopolamine has an excellent safety profile and has been used routinely for nearly 20 years for treatment of nausea due to surgery or motion sickness in adults and children. Scopolamine is available in the US only as a 1mg / 72 hours transdermal patch, and peak plasma levels are reached within 24 hours. This standard dosage level is very well tolerated in the general population.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Participants in Aim 2 will receive a placebo patch versus rivastigmine patch.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
Study: NCT04735198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary tumor surgery
Description: Large bowel resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary tumor surgery
Description: Large bowel resection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy
Description: Large bowel resection combined and cholecystectomy.
Study: NCT06086678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: 1. Deep breathing exercise.~2. Diaphragmatic breathing exercise.~3. Pursed lip breathing exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: 1. Deep breathing exercise.~2. Diaphragmatic breathing exercise.~3. Pursed lip breathing exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: 1. Deep breathing exercise.~2. Diaphragmatic breathing exercise.~3. Pursed lip breathing exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: 1. Water walking exercise.~2. Forward lunges exercise.~3. Single leg balance exercise.~4. Side stepping exercise.~5. Push ups exercise.~6. Standing knee lifts exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise in form of treadmill training when each child was standing on the treadmill, should be ensure that this standing in an upright position, and according to each child, the therapist corrected the height of the handrails. Ask the child to keep looking forwards along the walking on the treadmill aiming to encourage the setting of walking free. The treadmill training would be completed for each child when the child completes three stages in 1-min training cycles. First stage: the child grasped on to the rails with both hands in first 15 s of every 1-min. Second stage: the child grasped on to the railings with one hand in the second 15 s. And final stage: the child didn't grasp on to the railings in last 30 s. Every child performed this procedure twenty times
Study: NCT04716218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: back up head elevated position
Description: The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: back up head elevated position
Description: The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.
Study: NCT05246384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP7214
Description: RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP7214
Description: RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle
Study: NCT06386445

Intervention type: OTHER
Intervention: Serum metabolomics sequencing
Description: Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks，4 weeks，8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.